menu
    • menu
    [{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with Mydcombi Targeting 80 Million Patient in the U.S. Annually","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tropicamide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Concludes Type A Meeting with FDA Related to MydCombi\u2122 NDA Resubmission","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tropicamide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Tropicamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi\u2122 for In-Office Pupil Dilation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Reveals Positive Evidence That Optejet\u00ae Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Announces FDA Approval of Mydcombi\u2122, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company\u2019s Proprietary Optejet\u00ae Device Platform","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Phenylephrine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi\u2122 and Clobetasol Propionate Ophthalmic Suspension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."}]

    Find Clinical Drug Pipeline Developments & Deals for NCGC00024866-06

    Menu

    NCGC00024866-06

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionat...

                            Details : Mydcombi is FDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).

                            Brand Name : Mydcombi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 25, 2024

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages...

                            Details : Mydcombi is Eyenovia's USFDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).

                            Brand Name : Mydcombi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 08, 2023

                            Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Gl...

                            Details : Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).

                            Brand Name : Mydcombi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 12, 2023

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

                            Details : Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).

                            Brand Name : Mydcombi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 13, 2022

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Avenue Venture Opportunities Fund

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund

                            Details : The financing is intended to support manufacturing in anticipation of a MydCombi (tropicamide) launch and clinical supply for ongoing programs. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis and myopia...

                            Brand Name : Mydcombi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 29, 2022

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Avenue Venture Opportunities Fund

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

                            Details : MydCombi™ has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery.

                            Brand Name : MydCombi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 08, 2022

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with Mydcombi Targeting 80 Million Pa...

                            Details : The NDA submission follows the initial enrollment of the VISION-1 study, Eyenovia’s Phase 3 study for MicroLine in presbyopia, with top-line data expected the first half of 2021.

                            Brand Name : MydCombi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 29, 2020

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth